Pacira presents data showing lower healthcare costs for Exparel

Pacira (PCRX) BioSciences presented data from three real-world studies supporting the economic value of Exparel in total hip arthroplasty and total knee arthroplasty procedures performed in hospital outpatient department settings. “These real-world data continue to demonstrate the economic value that Exparel can deliver across outpatient orthopedic procedures,” said Brendan Teehan, chief commercial officer. “By helping reduce total healthcare costs, lowering opioid use, and supporting more efficient recovery in real-world settings, these data reinforce our commitment to advancing non-opioid pain management solutions that benefit patients, providers, and payers alike.”